Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Covid-19 Vaccine Responsiveness in Patients With Multiple Myeloma and Waldenstrom's Macroglobulinemia
This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
COVID-19 vaccines are designed to help prevent infections, hospitalizations, and death from the COVID-19 virus. Normally, when the vaccine is administered, the immune system reacts by creating antibodies (proteins made by the body's immune system to fight infections such as COVID-19) and helping the immune system's blood cells to fight it. In people with Multiple Myeloma and Waldenstrom's Macroglobulinemia, their immune system does not function normally, and an effective immune response may not occur. The research study procedures include screening for eligibility and the collection of data and biospecimens. It is expected that about 160 people will take part in this research study.
Effective immune response (EIR) rate at 28 days
Study Arms / Comparison Groups
Multiple Myeloma-MM patients
Description: People with Multiple Myeloma-MM receiving covid 19 vaccine
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
August 1, 2022
Primary Completion Date
November 1, 2021
Inclusion Criteria: - Age >18 years. - Lack of a contra-indication to a currently available COVID-19 vaccine. - Diagnosis of MM according to International Myeloma Working Group (IWMG) criteria (Cohort 1) or Diagnosis of WM according to WHO criteria (Cohort 2) - For treatment naïve WM patients (Cohort 2A): - Patient must have no prior history of anticancer treatment for WM. - The treating investigator must have no intention to initiate WM therapy within 2 months - For WM patients receiving BTK inhibitor (Cohort 2B): - Patient must have no history of cytotoxic chemotherapy within 1 year, and no history of other anticancer therapy within 6 months. - For currently or previously treated WM patients (Cohort 2C): - Patient must not be currently taking a BTK inhibitor or had recent exposure within 1 month of enrollment. Current or prior history of any other WM-directed therapy is allowed. Exclusion Criteria: -
18 Years - N/A
Andrew Branagan, MD, PhD, (617) 643-4000, [email protected]
Massachusetts General Hospital
Andrew Branagan, MD, PhD, Principal Investigator, Massachusetts General Hospital